A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Everolimus in Subjects With Neuroendocrine Tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2018
At a glance
- Drugs SNX 5422 (Primary) ; Everolimus
- Indications Neuroendocrine tumours
- Focus Adverse reactions
- Sponsors Esanex
- 27 Feb 2018 Planned End Date changed from 1 Oct 2017 to 31 Mar 2018.
- 25 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.
- 25 Apr 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History